




# PHARMACEUTICAL 2019

Regen BioPharma Inc  
Rank 351 of 363





# PHARMACEUTICAL 2019

Regen BioPharma Inc  
Rank 351 of 363

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 258% points. The greatest weakness of Regen BioPharma Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 249% points.

The company's Economic Capital Ratio, given in the ranking table, is -428%, being 465% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	43
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,674
Liabilities, Non-Current	0
Other Assets	166
Other Compr. Net Income	-35
Other Expenses	408
Other Liabilities	657
Other Net Income	-3,289
Other Revenues	100
Property and Equipment	0
Research and Development	374
Selling, General and Administrative Expense	744

Output Variable	Value in 1000 USD
Assets	209
Liabilities	9,331
Expenses	1,526
Revenues	100
Stockholders Equity	-9,122
Net Income	-4,715
Comprehensive Net Income	-4,733
Economic Capital Ratio	-428%